FibroGen Inc (NASDAQ:FGEN) CEO Sells $1,514,491.56 in Stock

FibroGen Inc (NASDAQ:FGEN) CEO Thomas B. Neff sold 39,636 shares of the firm’s stock in a transaction dated Thursday, June 6th. The stock was sold at an average price of $38.21, for a total value of $1,514,491.56. Following the sale, the chief executive officer now directly owns 2,480,780 shares in the company, valued at approximately $94,790,603.80. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

FGEN traded up $0.73 during trading on Monday, reaching $45.91. 515,200 shares of the stock were exchanged, compared to its average volume of 772,729. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.16 and a quick ratio of 6.16. FibroGen Inc has a 1 year low of $33.51 and a 1 year high of $68.55. The stock’s 50 day moving average price is $38.80. The firm has a market capitalization of $3.96 billion, a P/E ratio of -44.57 and a beta of 1.85.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.68) by $0.15. FibroGen had a negative return on equity of 17.71% and a negative net margin of 44.14%. The business had revenue of $23.90 million for the quarter, compared to the consensus estimate of $20.44 million. During the same period in the prior year, the business earned ($0.50) earnings per share. The business’s revenue was down 25.1% on a year-over-year basis. Equities research analysts anticipate that FibroGen Inc will post -0.87 EPS for the current fiscal year.

Several research analysts have commented on the company. Piper Jaffray Companies assumed coverage on FibroGen in a research report on Friday, April 12th. They set a “neutral” rating and a $65.00 price target on the stock. Mizuho cut their price target on FibroGen from $74.00 to $65.00 and set a “positive” rating on the stock in a research report on Friday, May 10th. Zacks Investment Research lowered FibroGen from a “buy” rating to a “hold” rating in a report on Tuesday, March 12th. BidaskClub lowered FibroGen from a “hold” rating to a “sell” rating in a report on Tuesday, April 16th. Finally, ValuEngine lowered FibroGen from a “buy” rating to a “hold” rating in a report on Friday, May 10th. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $61.57.

Large investors have recently modified their holdings of the company. FMR LLC increased its stake in FibroGen by 2.8% in the first quarter. FMR LLC now owns 10,029,786 shares of the biopharmaceutical company’s stock valued at $545,118,000 after purchasing an additional 269,570 shares during the last quarter. Vanguard Group Inc increased its stake in FibroGen by 1.8% in the third quarter. Vanguard Group Inc now owns 6,921,874 shares of the biopharmaceutical company’s stock valued at $420,503,000 after purchasing an additional 125,186 shares during the last quarter. Janus Henderson Group PLC increased its stake in FibroGen by 27.3% in the first quarter. Janus Henderson Group PLC now owns 2,208,759 shares of the biopharmaceutical company’s stock valued at $120,046,000 after purchasing an additional 473,042 shares during the last quarter. Hillhouse Capital Advisors Ltd. acquired a new position in FibroGen in the fourth quarter valued at $92,712,000. Finally, First Trust Advisors LP increased its stake in FibroGen by 11.3% in the first quarter. First Trust Advisors LP now owns 1,900,460 shares of the biopharmaceutical company’s stock valued at $103,290,000 after purchasing an additional 193,038 shares during the last quarter. Institutional investors and hedge funds own 66.27% of the company’s stock.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.

See Also: Do investors pay a separate front-end load every time they buy additional shares?

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.